Antiangiogenic therapy and p53

Science. 2002 Jul 26;297(5581):471; discussion 471.

Authors

Timothy Browder¹, Judah Folkman, Philip Hahnfeldt, John Heymach, Lynn Hlatky, Mark Kieran, Michael S Rogers

Affiliation

¹ Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.

PMID: 12143876

No abstract available

Publication types

Comment

MeSH terms

Angiogenesis Inhibitors / therapeutic use*
Animals
Genes, p53*
Growth Substances / metabolism
Humans
Mice
Neoplasms, Experimental / blood supply
Neoplasms, Experimental / drug therapy*
Neoplasms, Experimental / genetics
Neoplasms, Experimental / pathology
Neovascularization, Pathologic
Receptor Protein-Tyrosine Kinases / immunology
Receptor Protein-Tyrosine Kinases / metabolism
Receptors, Growth Factor / immunology
Receptors, Growth Factor / metabolism
Receptors, Vascular Endothelial Growth Factor
Tumor Cells, Cultured

Substances

Angiogenesis Inhibitors
Growth Substances
Receptors, Growth Factor
Receptor Protein-Tyrosine Kinases
Receptors, Vascular Endothelial Growth Factor